Quick pump upgrade may save hearts in shock
NCT ID NCT07655479
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study tests whether rapidly switching from a standard heart pump (Impella CP) to a more powerful one (Impella 5.5) within 24 hours after a heart attack improves outcomes for people in cardiogenic shock. About 115 adults aged 18-77 with severe shock will be enrolled. The goal is to see if this faster escalation reduces the need for strong medications and leads to fewer complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK POST MYOCARDIAL INFARCTION are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Impella heart pumps (Impella CP and Impella 5.5)
What this could lead to
If successful, this could establish a faster, more effective way to support the heart during cardiogenic shock, potentially reducing complications and improving survival.
What could go wrong
This is an early-stage trial with only 115 participants, so results may not apply to all patients. The procedure carries risks like bleeding or device-related complications.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.